BackTable Urology
Ep. 206 Biochemical Recurrence: Insights from AUA/ASTRO/SUO Guidelines with Dr. Todd Morgan
Dr. Todd Morgan
Time that we give ADT, minimum of four to six months for patients who are getting ADT, but 18 to 24 months recommended for patients with high-risk features who are undergoing RT. And then on top of that, there's ongoing research into intensification. And so meaning intensified hormone therapy, like adding enzalutamide or apalutamide.
0
💬
0
Comments
Log in to comment.
There are no comments yet.